11.75
price down icon1.51%   -0.18
after-market Dopo l'orario di chiusura: 11.75
loading
Precedente Chiudi:
$11.93
Aprire:
$11.9
Volume 24 ore:
204.55K
Relative Volume:
0.25
Capitalizzazione di mercato:
$640.80M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+7.50%
1M Prestazione:
+31.43%
6M Prestazione:
+1.25%
1 anno Prestazione:
+0.00%
Intervallo 1D:
Value
$11.69
$12.01
Intervallo di 1 settimana:
Value
$10.94
$12.03
Portata 52W:
Value
$7.80
$28.09

Bicara Therapeutics Inc Stock (BCAX) Company Profile

Name
Nome
Bicara Therapeutics Inc
Name
Telefono
617-785-8308
Name
Indirizzo
245 MAIN STREET, CAMBRIDGE
Name
Dipendente
0
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
BCAX's Discussions on Twitter

Confronta BCAX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
BCAX
Bicara Therapeutics Inc
11.75 642.98M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 122.48B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 31.91B 3.81B -644.79M -669.77M -6.24

Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-23 Aggiornamento Wells Fargo Underweight → Equal Weight
2025-04-17 Iniziato Wells Fargo Underweight
2025-02-06 Iniziato Wedbush Outperform
2024-12-06 Iniziato H.C. Wainwright Buy
2024-11-05 Iniziato Rodman & Renshaw Buy
2024-10-08 Iniziato Cantor Fitzgerald Overweight
2024-10-08 Iniziato Morgan Stanley Overweight
2024-10-08 Iniziato Stifel Buy
2024-10-08 Iniziato TD Cowen Buy
Mostra tutto

Bicara Therapeutics Inc Borsa (BCAX) Ultime notizie

pulisher
01:38 AM

What analysts say about Bicara Therapeutics Inc. stock outlookHigh-margin investment plays - jammulinksnews.com

01:38 AM
pulisher
Jul 24, 2025

Is Bicara Therapeutics Inc. stock a good hedge against inflationExtraordinary profit generation - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

Will Bicara Therapeutics Inc. stock benefit from interest rate changesDynamic investment growth - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 24, 2025

Is Bicara Therapeutics Inc. a good long term investmentConsistently exceptional gains - Autocar Professional

Jul 24, 2025
pulisher
Jul 23, 2025

Bicara Therapeutics Inc. Stock Analysis and ForecastFree Investment Community - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Bicara Therapeutics Inc. stock priceHigh-velocity gains - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

What analysts say about Bicara Therapeutics Inc. stockHigh-profit trading signals - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

How Bicara Therapeutics Inc. stock performs during market volatilityVolume Spike Monitors - Newser

Jul 22, 2025
pulisher
Jul 17, 2025

Analysts Set Bicara Therapeutics Inc. (NASDAQ:BCAX) Price Target at $31.86 - Defense World

Jul 17, 2025
pulisher
Jul 15, 2025

Why Bicara Therapeutics Inc. stock attracts strong analyst attentionFree Step-by-Step Investment Guide - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Bicara Therapeutics Inc. stock price move sharplyInvestor Friendly Risk Reward - Newser

Jul 15, 2025
pulisher
Jul 08, 2025

Merus, Bicara Present Promising HNSCC Trial Data at ASCO 2025, Advance Towards Phase III - Yahoo Finance

Jul 08, 2025
pulisher
Jun 25, 2025

GAMMA Investing LLC Purchases 7,694 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World

Jun 25, 2025
pulisher
Jun 12, 2025

Bicara Therapeutics Elects New Directors at Annual Meeting - TipRanks

Jun 12, 2025
pulisher
Jun 12, 2025

Petri Dish: Scorpion spinout debuts with $177M, Bicara doubles footprint - The Business Journals

Jun 12, 2025
pulisher
Jun 11, 2025

# Relay Therapeutics appoints Bicara CEO to board ahead of breast cancer trial - Investing.com

Jun 11, 2025
pulisher
Jun 11, 2025

Relay Therapeutics Strengthens Board with Precision Medicine Expert as Phase 3 Cancer Trial Approaches - Stock Titan

Jun 11, 2025
pulisher
Jun 11, 2025

Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus (NASDAQ:BCAX) - Seeking Alpha

Jun 11, 2025
pulisher
Jun 11, 2025

Bicara Therapeutics Inc. (NASDAQ:BCAX) Holdings Raised by Bank of America Corp DE - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Estimates BCAX FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Morgan Stanley Maintains Buy Rating on Bicara (BCAX) After the Ficerafusp Alfa Trial Update - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

Stifel maintains Buy rating, $48 target on Bicara Therapeutics stock By Investing.com - Investing.com Nigeria

Jun 10, 2025

Bicara Therapeutics Inc Azioni (BCAX) Dati Finanziari

Non sono disponibili dati finanziari per Bicara Therapeutics Inc (BCAX). Controlla altri titoli per ulteriori informazioni.

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Bicara Therapeutics Inc Azioni (BCAX) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Meisner Lara
Chief Legal Officer
Jun 16 '25
Sale
10.43
15,829
165,096
0
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Capitalizzazione:     |  Volume (24 ore):